# Akari Therapeutics (AKTX) — Overview

AKTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/aktx

## Price

Last close $8.84 on Oct 15, 2026. 52-week range $3.06 – $32.80.

## Company profile

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $0.00 |
| Revenue (quarter) | $0.00 |
| Revenue growth (year over year) | 0.00% |
| Gross profit (trailing twelve months) | $0.00 |
| Gross margin | 0.00% |
| Net income (trailing twelve months) | $0.00 |
| Net income (quarter) | −$4.8M |
| Net income growth (year over year) | -153.67% |
| Net margin | 0.00% |
| Return on equity | -140.09% |
| EPS (trailing twelve months) | $0.00 |
| Book value per share | $10.62 |
| P/E (trailing twelve months) | — |
| Price to book | 1.1 |
| Debt to assets | 51.86% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### How do I buy stock in Akari Therapeutics (AKTX)?

AKTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).